Diversifying clinical trials
- PMID: 30523324
- DOI: 10.1038/s41591-018-0303-4
Diversifying clinical trials
Abstract
Scientific common sense and social justice dictate that the safety and efficacy of new therapies must be tested in the patient populations in need of treatment. Yet a recent study found that African Americans have been dramatically underrepresented in US clinical trials for cancer drugs. Efforts to increase the participation of minorities in clinical trials must become a priority for all drug developers.
Comment in
-
Coronavirus R number hides raised risk for minority ethnic groups.Nature. 2020 Jun;582(7812):341. doi: 10.1038/d41586-020-01740-8. Nature. 2020. PMID: 32523073 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical